A股異動丨幽門螺旋桿菌被列為明確致癌物 相關概念股再度暴漲
格隆匯1月6日丨繼昨天掀漲停潮後,幽門螺旋桿菌概念股今天再度暴漲,科拓生物、亞太藥業和均瑤健康強勢漲停。近日,在美國衞生與公眾服務部(HHS)發佈的第15份致癌物報吿中,幽門螺桿菌導致的慢性感染被列為明確人類致癌物。相關話題登上微博熱搜。根據2001-2014全國幽門螺旋桿菌調查顯示,我國的幽門螺旋桿菌感染率在40%-90%之間,平均為59%。根據央視網報道,我國兒童幽門螺旋桿菌平均感染率40%。均瑤健康曾表示將推出“抗幽門螺旋桿菌”的飲料;科拓生物旗下擁有針產品“益適優”,是針對幽門螺桿菌益生菌飲品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.